Harnessing the power of deep learning on 3D molecular configurations to deliver medicines of transformational efficacy to patients.
Location: United Kingdom
Employees: 11-50
Total raised: $130.11M
Founded date: 2021
Founders name: Laksh Aithani
Investors 5
| Date | Name | Website |
| 24.08.2022 | Khosla Ven... | khoslavent... |
| - | F-Prime Ca... | fprimecapi... |
| 10.06.2022 | OrbiMed | orbimed.co... |
| - | Sahsen Ven... | sahsen.com |
| - | Axial VC | axialvc.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.09.2025 | Series B | $80.11M | New Enterp... |
| 18.06.2022 | Series A | $50M | F-Prime Ca... |
Persons 19
| Date | First Name | Last Name | Title | Location | |||
| - | Martin | Taylor | Member of ... | linkedin.c... | - | m****n@cha... | - |
| - | Laksh | Aithani | Founder, C... | linkedin.c... | - | l***h@char... | - |
| - | Prakash | Rucktooa | Director &... | linkedin.c... | - | p*****h@ch... | - |
| - | Nakul | Khanna | Senior Sof... | linkedin.c... | - | n***l@char... | - |
| - | Daniel | Low | Senior Sof... | linkedin.c... | - | d****l@cha... | - |
| - | Jelena | Habjanič | Senior Sci... | linkedin.c... | - | j****a@cha... | - |
| - | Sergey | Bartunov | Director o... | linkedin.c... | - | s****y@cha... | - |
| - | Gaya | Nulens | Talent Acq... | linkedin.c... | - | g**a@charm... | - |
| - | Sarah | Skerratt, ... | SVP, Head ... | linkedin.c... | - | S***h@char... | - |
| - | Zahra | Khwaja | Business D... | linkedin.c... | - | z***a@char... | - |
Show more
Mentions in press and media 11
| Date | Title | Description |
| 07.09.2025 | Charm Therapeutics Secures $80M for AI-Driven Cancer Battle | Charm Therapeutics, a London-based biotech firm, clinched $80M in Series B funding. This investment fuels its AI-driven drug discovery platform. The company targets precision oncology, focusing on acute myeloid leukemia (AML). Its lead meni... |
| 02.09.2025 | London’s CHARM Therapeutics raises €68.5 million financing to tackle treatment-resistant cancers | British BioTech startup CHARM Therapeutics, announces closing of an oversubscribed Series B funding round, raising €68.5 million to advance its next generation menin inhibitor into clinical development. The funding round was co-led by New E... |
| 02.09.2025 | Charm Therapeutics Raises $80M in Series B Financing | Charm Therapeutics, a London, UK-based biotechnology company which specializes in precision oncology treatments, raised $80M in Series B funding. The round was led by New Enterprise Associates (NEA) and SR One, with participation from exist... |
| 19.03.2024 | CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) | - |
| 18.06.2022 | London-based cancer treatment startup CHARM Therapeutics raises USD 50 million in Series A | LONDON, June 9, 2022 — CHARM Therapeutics, a 3D deep-learning research company founded by David Baker, Ph.D., and Laksh Aithani to discover and develop transformational medicines, has announced a US $50 million Series A financing led by F-P... |
| 10.06.2022 | London’s Charm Therapeutics raises $50 million as it takes on cancer treatment | Charm Therapeutics has raised $50 million in a Series A funding round co-led by F-Prime Capital and OrbiMed. The capital is slated to be used to further the company’s ambitions of transforming structure-based drug discovery, namely via its ... |
| 10.06.2022 | Charm Therapeutics applies AI to complex protein interactions, locking down $50M A round | The world of AI-powered drug discovery keeps expanding as the capabilities of machine learning grow. One approach that seemed unthinkable just a few years ago is simulating the complicated interplays of two interlocking molecules — but that... |
| 09.06.2022 | David Baker, head of Seattle’s Institute for Protein Design, launches London biotech startup | IPD director David Baker. (IPD Photo) Prolific biotech co-founder and University of Washington scientist David Baker, head of the UW Institute for Protein Design, has launched a new company. Charm Therapeutics, based in London, harnesses de... |
| - | London’s Charm Therapeutics raises $50 million as it takes on cancer treatment | Charm Therapeutics has raised $50 million in a Series A funding round co-led by F-Prime Capital and OrbiMed. The capital is slated to be used to further the company’s ambitions of transforming structure-based drug discovery, namely via its ... |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months. Here are the 23 companie... |
Show more